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Introduction: The impact of pulmonary nontuberculous mycobacterial (pNTM) disease on
health-related quality of life (HRQL) has not been quantified.
Methods: We performed a prospective observational study of HRQL in 51 patients with pNTM
disease. One generic (Short-form 36, version 2 -SF-36), and one pulmonary disease-specific
instrument (St. George’s Respiratory Questionnaire e SGRQ) were administered to each
subject.
Results: Fifty-one patients with pNTM disease from one ambulatory clinic were enrolled. The
mean (sd) age was 67 (10) years and 80% (41/51) were female. The most common causative
NTM was MAC in 84% (43/51) followed by Mycobacterium abscessus in 8% (4/51). Radiographic
disease type was nodular bronchiectasis in 71% (36/51) and fibrocavitary in 22% (11/51). For
SF-36, most raw scores were at least 10 points below Canadian population-based normals,
and all normbased scores were below the expected normal value of 50. For SGRQ, all scores
were worse by 25 points compared with published normals. In multivariable analyses, only
FVC and DLCO were significantly associated with SF-36, and only FVC and emphysema were
significantly associated with SGRQ.
Conclusion: Patients with pNTM disease have significantly impaired HRQL that is most closely
associated with lung function and not readily explained by age, sex or extra-pulmonary comor-
bidity.
ª 2011 Elsevier Ltd. All rights reserved.tern Hospital, 7E-452, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada. Tel.: þ1 416 603 5767;
nto.ca (T.K. Marras).
1 Elsevier Ltd. All rights reserved.
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Pulmonary nontuberculous mycobacterial (pNTM) infection
is an increasingly common problem1e3 that requires complex
assessment and management. Treatment comprises pro-
longed multi-drug therapy, often associated with significant
toxicities and often not curative.4,5 The disease is frequently
chronic,4 due to an inability to eradicate the infection,
recurrence after apparently successful therapy, or from
intolerance of therapy. The important side effects from NTM
therapy suggest that there is a significant trade-off involved
in undertaking medical treatment.5
Assessing health-related quality of life (HRQL) can inform
patient management and policy decisions.6HRQL involves
assessing a patient’s perception of performance in physical
function, emotional state, social interaction and somatic
sensation domains,7measuredwith either generic or disease-
specific instruments. Generic instruments, like Medical
Outcomes Short-Form e 36 version 2 (SF-36), provide sum-
maries of HRQL and can be used in different diseases.8,9
Disease-specific questionnaires focus on one condition and
relevant areas of function.7 The St. George’s Respiratory
questionnaire (SGRQ) is a respiratory disease-specific HRQL
instrument, designed originally to measure the impact of
COPD on overall health, well-being and daily life.10
There are few published data regarding HRQL in pNTM.
In one abstract,11 the SGRQ had good repeatability and
validity in pulmonary Mycobacterium avium complex (MAC)
infection, suggesting that the SGRQ may be a useful
disease-specific instrument in pNTM.11 However, the pres-
ence and magnitude of HRQL impairment in pulmonary NTM
has not been evaluated. It is important to establish and
quantify the impact of NTM on HRQL, develop an under-
standing of factors that contribute to HRQL impairment in
this setting, and provide a method to evaluate effects of
therapy. We conducted a cross-sectional study of HRQL in
pNTM. Our primary objective was to measure HRQL in pNTM
using the SF-36 and SGRQ and investigate whether impaired
HRQL might be explained by specific disease characteristics
or comorbidities. Our secondary objective was to assess
some characteristics of the SF-36 and SGRQ in pNTM.
Methods
We performed an observational, cross-sectional study of
HRQL in patients who fulfilled American thoracic society
(ATS) criteria for pNTM disease, including presence of
clinical symptoms, recruited by convenience sampling
during a routine clinic visit between August 2008 and July
2009 from one ambulatory clinic at our institution. Only
patients known to fulfill ATS disease criteria were
approached for consent and no patients declined partici-
pation. This study was approved by our institutional ethics
board and patients provided written consent before HRQL
data were gathered.
One generic (SF-36) and one pulmonary disease-specific
(SGRQ) instrument were administered to each participant.
The Modified Cumulative Illness Rating Scale (CIRS) was
used to quantify comorbidity burden.12 All questionnaires
were completed in written format and in the presence of
one of the authors (MM), for technical assistance andverification of completion. Investigators reviewed records
of all subjects regarding presence of underlying lung
disease, microbiologic burden of infection, and nature and
distribution of abnormalities on CT scans (as interpreted by
one author (TM)). Every patient had at least one CT scan as
part of their assessment. Radiographic disease type
(nodular bronchiectasis - NB or fibrocavitary - FC) was
determined by the predominant radiographic abnormality.
Patients were classified as having NB if the first available CT
scan demonstrated small nodules and bronchiectasis either
without cavitation or with cavities comprising a minority of
the overall abnormalities. Patients were classified as having
FC if the first available CT scan demonstrated cavitation
(þ/ linear fibrotic opacities) as the exclusive or dominant
radiographic abnormality. Patients were classified as having
emphysema if they had a smoking history of at least 10 pack
years and had emphysema visible on the CT scan, as
reported by the chest radiologist. Treatment status was
classified as (a) not on treatment and not currently
required (clinician’s impression), (b) on treatment <3
months or not on treatment but treatment advisable
(clinician’s impression), or (c) on treatment for >3 months.
For the primary objective of describing HRQL in pNTM,
SF-36 raw scores were compared with Canadian population
normals13 using t-tests. Component summary scores were
normalized (mean (sd) 50 (10)).14 For the SGRQ, scores
were compared with population normals15 using t-tests.For
the primary objective regarding associations between HRQL
and clinical factors, sub-groups defined by sex, emphysema
and radiologic disease type (nodular bronchiectasis - NB or
fibrocavitary - FC) were compared using t-tests for illus-
trative purposes. However, the primary analysis comprised
multivariable models, wherein SF-36 physical component
score (PCS) and SGRQ total score were each modeled
separately using age, sex, non-pulmonary comorbidity,
emphysema, percent predicted FVC, FEV1 and DLCO, AFB
smear status, cavitation on CT, and NB disease on CT. These
variables were selected based on clinical impression of
a potential impact on HRQL and demonstrated relevance to
HRQL scores.13,15 A p value <0.05 was considered signifi-
cant. For the secondary objective, regarding internal
consistency, we calculated Cronbach’s alpha for the SF-36
and SGRQ. For construct validity, we studied associations
between pulmonary function variables (percent predicted
forced vital capacity e FVC%; percent predicted 1-s forced
expiratory volume - FEV1%, and percent predicted diffusion
capacity for carbon monoxide e DLCO%) and scores on the
SGRQ and SF-36. Previous work suggests MIDs of 5e10 for
the SF-36,16,17 and 4e5 for the SGRQ.7 We estimated
distribution-based MIDs for SF-36 and SGRQ, using 1/2 the
standard deviation (1/2SD) or 1 standard error of the mean
(1SEM).18 Statistical analyses were performed using SAS
8.02 (SAS Institute, Cary, North Carolina, U.S.A.), Microsoft
Office XL 2007 (Microsoft, Redmond, Washington U.S.A.),
and GraphPad online calculator (http://www.graphpad.
com, accessed December 29, 2010).Results
Characteristics of the 51 patients with pNTM disease (ATS
definition) are summarized in Table 1 (and supplementary
Table 1 Clinical, microbiological, radiological and pul-
monary function characteristics of patients with pulmonary
NTM disease.
Category N Z 51
Age e years (mean (sd)) 67 (11)
Female Sex 41 (80%)
Microbiology
Species
- MAC 43 (84%)
- M. abscessus 4 (8%)
- Other 4 (8%)
Number of positive cultures
[median (quartiles)]
13 (10, 22)
Patients with 1 AFB smear positive
specimen at any time
25 (49%)
AFB smear 1 at time of study 14 (27%)
Treatment Status
- On treatment 28 (55%)
 Less than 3 months 2 (4%)
 Greater than 3 months 26 (51%)
- No Current Treatment 23 (45%)
 Had previous treatment 13 (25%)
 Never had treatment 8 (16%)
 Needs treatment 2 (4%)
Underlying Lung Conditions 23 (45%)
- Prior TB 5 (10%)
- Emphysema 8 (16%)
- Other 10 (20%)
Radiologic Disease Type
- Nodular bronchiectasis 36 (71%)
- Fibrocavitary 11 (22%)
- Unclassifiable 4 (8%)
Radiographic Distribution
- Middle lobe/lingula 21 (41%)
- Upper lobes 20 (39%)
- Lower lobes 5 (10%)
- Diffuse/unclassifiable 7 (14%)
Imaging: CT
- Nodules 49 (96%)
- Cavity/Cavities 23 (45%)
- Bronchiectasis 39 (77%)
- Consolidation 21 (41%)
- Masses 4 (8%)
Clinical
- Cough 50 (98%)
- Sputum 50 (98%)
- Hemoptysis 13 (25%)
- Dyspnea 18 (35%)
- Chest pain 12 (24%)
- Fatigue 25 (49%)
- Weight Loss 16 (31%)
- Fever 12 (24%)
- Sweats 11 (22%)
- Anorexia 1 (2%)
Pulmonary Function
- FVC - % predicted (mean (sd)) 81% (23)
- FEV1 - % predicted (mean (sd)) 66% (26)
- DLCO - % predicted (mean (sd)) 70% (21)
1720 M. Mehta, T.K. MarrasTable 1). Patients tended to be middle-aged to older
women, most commonly infected with M. avium complex
(MAC), and 55% were receiving therapy at time of study. NB
was the most common CT abnormality. Overall, 41% had
mid-lung and 39% had upper lung predominant disease and
45% had some degree of cavitation on CT. The median
(interquartile range) number of positive cultures per
patient was 13 (10e22). AFB smear positive specimens were
seen at some time in 49% of patients, and in 27% at the time
of study. Underlying lung disease was present in 45%, the
most common of which was emphysema, in 16%. Emphy-
sema was present in only 6% (2/36) of patients with NB, but
in 55% (6/11) of patients with FC.
Mean SF-36 normbased scores, in all domains and
summary scores, were worse than the expected value of 50,
and medians were all >5 points below normal (established
MID 5e10 points, Table 2). Physical functioning, role phys-
ical, general health perceptions and social functioning were
all >20 points below normal. Bodily pain and energy and
vitality were both >10 points below normal. All differences
from normal values were statistically significant
(p < 0.001). For the SGRQ, median scores were >25 points
worse than normal values (established MID 4e5) in all
domains and all comparisons were statistically significant
(p < 0.001, Table 3).
For both SF-36 and SGRQ, scores remained worse than
normal by sex. There was no statistical difference between
males and females for all categories of SGRQ and for all
except role physical for SF-36. Men tended to have worse
scores for the SF-36 (by 1.9e27.1 points in all domains
except mental health) and SGRQ (5.1e12.5 points in all
domains), but the small number of men (n Z 10) limits sex
comparisons. There were no important differences identi-
fied between patients not receiving treatment versus
receiving treatment >3 months. Patients with emphysema
tended to have worse SF-36 physical function and role
physical scores, but the differences were not statistically
significant (Table 4). SGRQ scores of patients with emphy-
sema were worse in all categories, with statistical signifi-
cance evident in all domains except impacts (Table 5). SF-
36 normbased scores and SGRQ scores were significantly
worse than normal in almost all categories, in both NB and
FC disease. Patients with FC tended to have worse SF-36
scores, predominantly in physical functioning (p Z 0.03)
and mental health category (p Z 0.09, Table 4) and worse
SGRQ scores in all domains, with statistically significant
differences in three domains (Table 5).In univariate
regression models, higher FVC%, FEV1% and DLCO% were all
associated with better SF-36 PCS, while higher FVC%, FEV1%
were associated with better SGRQ total scores. We studied
HRQL scores in subsets by NTM species, grouped by MAC,
Mycobcterium abscessus and others. There was a tendency
for worse SGRQ scores in patients with M. abscessus (by
5e10 units in symptoms, impacts and total), but there were
no statistically significant differences. There were no
important differences detected in SF-36 between NTM
species. Analyses by species were limited by the very small
number of patients with species other than MAC (M.
abscessus e 4, other non-MAC e 4). The primary analysis to
investigating associations between clinical features and
HRQL used a multivariable model for each of SF-36 PCS and
SGRQ total score. We modeled SF-36 PCS using age, sex,
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Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease 1721non-pulmonary comorbidity (supplementary Table 1),
emphysema, FVC%, FEV1%, DLCO%, AFB smear status, CT
cavitation, and NB disease. The only significant predictors
of a better SF-36 PCS were higher FVC% (p < 0.0001) and
higher DLCO% (p Z 0.03) (Supplementary Table 2).
Supplementary analyses modeled all SF-36 domain scores
(norm based) using the above variables, wherein better SF-
36 scores were associated with higher FVC% for most
domains, while other associations were inconsistent
(Supplementary Table 2). The corresponding primary anal-
ysis for SGRQ, modeled total score using age, sex, non-
pulmonary comorbidity (Supplementary Table 3), emphy-
sema, FVC%, FEV1%, DLCO%, AFB smear status, CT cavita-
tion, and NB disease. Lower FVC% (p < 0.0001) and the
presence of emphysema (p Z 0.03), were both associated
with worse SGRQ total scores. Supplementary analyses
modeled all SGRQ domain scores using the above variables,
wherein lower FVC% and emphysema were associated with
worse activity and total scores (Supplementary Table 3).
As a secondary objective, we investigated some perfor-
mance characteristics of the SF-36 and SGRQ. For the SF-36
internal consistency, Cronbach’s alpha was high
(0.81e0.92) for all components and summary scores (Table
2). There appeared to be good construct validity, in that
there was a strong association between SF-36 and SGRQ
scores for all domains in all models, and a higher FVC% was
associated with better SF-36 scores in the primary model
and most additional models (Supplementary Table 2).
Regarding SGRQ internal consistency, Cronbach’s alpha was
moderately-high (0.72e0.92) for all components and
summary scores (Table 3). There appeared to be good
construct validity, in that there was a strong association
between SGRQ and SF-36 scores for all domains in all
models, and a higher FVC% was associated with better SGRQ
scores in all models (Supplementary Table 3). We used two
distribution-based methods to estimate MID for the SF-36
and SGRQ (1SEM and 1/2SD, Supplementary Table 4). MID
ranges for the SF-36 were 1.6e2.1 by 1SEM and 5.6e7.4 by
1/2SD. Estimates using 1/2SD appear closest to established
SF-36 MID (5e10 points). MID for domains and total SGRQ
scores were 3.2e3.8 for 1SEM and 11.5e13.4 for 1/2SD.
Estimates using 1SEM appear closest to established SGRQ
MID (4e5 points).Discussion
In our detailed study of HRQL in pNTM, we observed
significant impairments in both SF-36 and SGRQ. SF-36
scores indicated greatest impairment in physical function.
This finding reinforces our clinical impression that this
disease has a major impact on HRQL. We are unaware of
other published data regarding the magnitude of impair-
ment of HRQL in pNTM. However, many studies have looked
at HRQL in other chronic conditions. In a study of common
chronic conditions ischemic heart disease significantly
affected many physical health scales; diabetes impacted
general health and arthritis impacted bodily pain, while SF-
36 PCS was impacted most by arthritis, chronic lung disease
and congestive heart failure.19 However, the SF-36 scores
from our patients were worse still in each category. In
a study of SF-36 in COPD, independent of comorbidity,
Table 3 SGRQ scores of patients with pNTM disease.
Category N Symptoms Activity Impacts Total
Mean (sd)b 51 39.9 (24) 49.1 (27) 32.8 (25) 39.0 (23)
Median (iqr)b 51 36.9 (20e59) 47.7 (31e73) 24.9 (12e53) 20.4 (20e58)
Internal consistencyd e 0.72 0.90 0.89 0.92
Population Normal e Mean (sd) 862 9.7 (13.2) 13.4 (17.6) 4.7 (9.9) 8.4 (11.3)
Difference (Normal e NTM)a -p value e 30.2 (<0.001) 35.7 (<0.001) 28.1 (<0.001) 30.6 (<0.001)
Floor is defined as any score from 95 to 100 and ceiling defined as any score from 0 to 5.
a NTM scores subtracted from population normal (negative value indicates worse HRQL in NTM); minimal important difference in SGRQ
is 4e5 points.
b Lower SGRQ scores indicate better HRQL.
d Cronbach’s alpha.
1722 M. Mehta, T.K. Marrasreduced HRQL was seen in all domains, but most prominent
in physical functioning (28), role functioning (22),
vitality (14), and general health (26), and minor or not
significant for social functioning (6), mental health (1),
role function emotional (3), and bodily pain (3).20 In our
patients, SF-36 scores were impaired in all categories
including mental health. It appears that patients with pNTM
disease have significantly impaired HRQL that is at least as
severe as several common chronic diseases. HRQL after
treatment for pulmonary TB has also been shown to be
impaired, although much less than in our findings in active
pNTM disease.21 This finding is not unexpected, since we
tested patients with active pNTM, as opposed to patients
with prior treated pulmonary TB.
In studying associations between clinical features and
HRQL, multivariable analyses identified only lower FVC% to
be significantly linked to poorer scores in both SF-36 and
SGRQ. Lower DLCO% was associated with poorer SF-36 PCS,
and emphysema was associated with poorer SGRQ scores.
Although we expected to observe differences in HRQL
between different radiographic types of NTM disease (NB
versus FC), this was not the case in multivariable analyses.
Patients with NB appeared to have better scores on
univariate analyses in some domains but this may have been
due to less emphysema (6%, 2/36 versus 55%, 6/11) and less
comorbidity (by modified CIRS index) among patients with
NB. Impaired HRQL in emphysema is well-known,22,23 and
was a significant factor in multivariable analyses for most
SGRQ components. However, emphysema was not associ-
ated with SF-36, suggesting a complementary role for
disease-specific and generic HRQL instruments in pNTM
disease. Lung function, measured by FVC% was most
consistently important, regardless of instrument or domain.
There were no consistent associations between HRQL and
sex, age or extra-pulmonary comorbidities. HRQL scores for
both men and women were below normal. Although men
tended to score worse, differences were not usually
statistically significant and we did not observe a sex
difference in multivariable analysis, suggesting that HRQL is
impaired similarly in both men and women with pNTM,
similar to the situation in asthma and COPD.22,24 However,
this should be interpreted cautiously given the small
number of men in our study. HRQL for patients not receiving
anti-mycobacterial therapy were not significantly different
than for patients on therapy for >3 months. One might
assume that if antibacterial treatment is effective, thatscores should be lower in patients on established therapy.
To study treatment would require randomization of simi-
larly ill patients to therapy versus control, which was not
done in our observational study of HRQL. Patients who were
not on treatment generally had been judged to have less
severe illness that did not require antibacterial therapy.
The lack of a difference in HRQL between treated and
untreated patients is therefore not surprising. Overall, it
appears that HRQL impairment in pNTM is primarily due to
lung disease, rather than extra-pulmonary comorbidity, age
or sex.
We estimated the MID for both SF-36 and SGRQ using
statistical methods (1SEM and 1/2SD). 1SEM may represent
the lowest possible MID, since a change smaller than this
likely represents a measurement error.25 On the other
hand, it has been argued that a standard deviation,
although meaningful, may not be minimal.18 To best esti-
mate the MID, one should have longitudinal data and use
clinically relevant anchors as benchmarks. In the absence
of such data, one might consider an interim range for MID
for the SF-36 (1.6e5.6 for PCS) and SGRQ (3.2e11.5 for
total) in pNTM, that lies between 1SEM and 1/2SD. To
understand whether the SF-36 and SGRQ are useful in
pNTM, we assessed their internal consistency using Cron-
bach’s alpha. The results demonstrated good internal
consistency, construct validity and distribution-based MIDs
(approximating MIDs in other conditions) so the two
instruments do appear to be promising for use in patients
with pNTM disease, but it will be important to thoroughly
establish the validity and responsiveness of these instru-
ments in further studies. Further investigation of these
instruments is warranted and we hope that these instru-
ments can be used as tools in studies of pNTM to understand
group comparability and possibility response to therapy in
clinical trials.
We are aware of one abstract in which HRQL was studied
in pNTM, wherein the validity of the SGRQ was assessed in
69 patients with MAC lung disease.11 The internal consis-
tency was similar to our findings (Cronbach’s alpha >70)
and in 34 patients who had the SGRQ repeated two weeks
later, the intraclass correlation coefficient was also high
(>0.85). Construct validity, assessed by correlation with
pulmonary function, SF-36 and anxiety scores and appeared
to be good. We assessed construct validity by studying the
association between SF-36 and SGRQ, and similarly found
strong associations in all multivariable models, supporting
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Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease 1723the notion that these instruments have good construct
validity in pNTM disease. We also observed very strong
associations between pulmonary function and HRQL scores.
In the published abstract, the internal consistency and
validity of the SGRQ were thoroughly assessed, but no data
were presented on the extent of HRQL impairment.11 Our
findings are similar regarding consistency and validity of the
SGRQ and SF-36, and further demonstrate that pNTM
disease is associated with significantly impaired HRQL.
There is a trade-off in undertaking treatment for NTM
lung disease given that the treatments may be associated
with significant adverse effects. With a larger sample size,
including groups of patients about to begin therapy, it may
be possible to assess whether formal HRQL measurements
might provide information to help decide which patients
should be treated. However, our sample was inadequate to
study this issue and further, we believe it might be
impractical to provide a clinical decision tool based on
somewhat complex instruments like the SF-36 or SGRQ. The
strong association between FVC and HRQL raises the ques-
tion of whether simple spirometry may comprise an
adequate surrogate for formal measures of HRQL. Based on
our analyses, we think that formal HRQL measures will
likely be more useful. The r-square values for our models,
that variably included an additional significant predictor,
ranged from approximately 0.25e0.40, suggesting that the
models, although containing important predictive infor-
mation, did not nearly explain all of the variability in HRQL.
Because of their purpose driven development, we think
that formal measures of HRQL will provide a meaningful
assessment of well-being or quality of life and have the
potential to provide useful discriminative and evaluative
information for determining severity of HRQL impairments
and assessing changes over time respectively. These
features would be particularly useful in assessing group
comparability and treatment effects in research settings.
Our study has some important limitations. First, our
sample is limited in size and came from a single clinic.
Creating sub-groups further reduced sample size for indi-
vidual analyses, limiting inferences that could be made. It
is possible that there could be a referral bias, since the NTM
clinic sees patients referred from specialists (pulmonary
and infectious diseases) as well as primary care physicians.
Patients referred from specialists could have had more
severe or complex disease. However, we think that our
patients were characteristic of patients with pNTM gener-
ally reported (majority females with MAC NB). Another
limitation is the paucity of normal population data for the
SGRQ. We compared our Canadian patients’ SGRQ scores
with those of a Spanish cohort.15 There may be important
differences in SGRQ scores between nations, but we lacked
more appropriate comparison values. Our multivariable
analyses addressing secondary objective may have been
overfit, because we entered a relatively large number of
predictor variables (n Z 10) into a model with a relatively
small number of observations (n Z 51). Although some
authors recommend a ratio of 10 observations per predictor
variable to avoid overfit linear regression,26 others suggest
a minimum ratio of 5e127 is acceptable. We decided that it
was appropriate to enter a relatively large number of
variables because of the absence of any data directly
applicable to pNTM. Our comorbidity evaluation was based
Table 5 SGRQ scores (mean (sd)) by presence of emphysema or radiographic disease type.
Category n Symptoms Activity Impacts Total
Emphysema 8 56.5 (13.4) 73.8 (13.9) 44.4 (24.2) 55.4 (17.5)
No Emphysema 43 36.9 (24.8) 44.4 (26.3) 30.6 (24.5) 36.0 (22.7)
P value e 0.0353 0.0035 0.1492 0.0266
Nodular Bronchiectasis 36 35.3 (23.0) 41.6 (26.8) 29.8 (25.2) 34.4 (23.0)
Fibrocavitary 11 52.2 (24.1) 67.4 (14.5) 38.2 (24.2) 49.4 (19.2)
P value e 0.0399 0.0039 0.3316 0.0551
*P values for comparing scores of patients with versus without emphysema or nodular bronchiectasis versus fibrocavitary disease type
(t-test).
Total patients with nodular bronchiectasis and fibrocavitation sums to less than 51 because 4 patients could not be classified according to
this scheme.
1724 M. Mehta, T.K. Marrason patient self-report, which is generally accurate.28,29
Although in some diseases, such as those involving loco-
motion, there is discrepancy between medical records and
questionnaires,28 we decided that supervised self-report
questionnaire was the most feasible approach to yield
accurate results. Finally, our cross-sectional design
precluded studying instrument responsiveness, and best
assessing MIDs. However, distribution-based MID may be
relatively accurate,18 and our distribution-based estimates
were in the same range as reported for these instruments
from other populations. Furthermore, in a cross-sectional
study, it is impossible to rigorously assess the impact of
NTM treatment on HRQL, because patients on treatment
will undoubtedly be systematically different than those on
therapy. Patients on treatment likely have more significant
disease (presumably translating into worse HRQL) but
possibly are well enough to embark upon and endure the
long-term, multi-agent antibacterial therapy (possibly
translating into better HRQL). A very large cross-sectional
study, with significant numbers of patients in different
treatment groups (not on therapy and judged not to need
therapy, newly started on therapy, on therapy for at least
3e6 months, prior therapy without relapse and prior
therapy with relapse) could be used to infer effects of
treatment on HRQL, but our study was too small to provide
such information. To rigorously assess the effect of treat-
ment on HRQL, one would need a placebo controlled
randomized trial of therapy, or a longitudinal study.
Given the fact that we observed a strong association
between pulmonary function and HRQL, comparing pulmo-
nary function between patients in our cohort and others
reported in the literature could potentially provide a useful
index of how typical our patients might be and thus the
generalizability of our results. We are aware of two over-
lapping studies that focused on pulmonary function in pNTM
disease, both of which focused exclusively on pMAC patients
and excluded patients with any other known lung dis-
ease.30,31Although there was no index of disease severity
provided, it appears that patients had relatively mild
disease, in that none had been previously treated. From this
very small sample of 15 patients with pMAC and no other lung
disease, it was observed that the mean (% predicted): FEV1
was 80%, FVC was 113%, and DLCO was 100%.31 In contrast,
we observed in our cohort that the mean (% predicted): FEV1
was 66%, FVC was 81%, and DLCO was 70%. Our cohort was
selected differently. We included all patients with pNTM
disease seen in a pNTM clinic, regardless of underlying lungdisease and included patients of all disease severities. Forty-
five percent of patients in our cohort had cavitation on CT
scan and 80% were either on treatment or had been treated
in the past. We think that our patients comprised a pop-
ulation with more severe pNTM disease as well as underlying
lung disease that makes it very difficult to compare the
cohorts by pulmonary function.
In summary, patients with pulmonary NTM disease have
significantly impaired HRQL, by both SF-36 and SGRQ. The
impairments appear to be closely related to lung function
as measured by FVC, and to a lesser extent DLCO and
emphysema, but cannot be explained by age and extra-
pulmonary comorbidity. The SF-36 and SGRQ appear to be
valid instruments in pNTM disease.
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